MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Surmodics Accounts Receivables 2011-2026 | SRDX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.3 M | 10.8 M | 10.5 M | 9.17 M | 7.68 M | 8.99 M | 8.88 M | 7.21 M | 6.87 M | 7.48 M | 4.75 M | 5.33 M | 5.07 M | 7.69 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 M | 4.75 M | 8.12 M |
Quarterly Accounts Receivables Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.2 M | 11.6 M | 12.6 M | 13.3 M | 13.4 M | 12.3 M | 12.9 M | 10.8 M | 11.8 M | 12.1 M | 10.1 M | 10.5 M | - | 11 M | 8.01 M | 9.17 M | 8.6 M | 9.17 M | 8.06 M | 7.68 M | 7.68 M | 7.68 M | 7.68 M | 8.99 M | 8.99 M | 8.99 M | 9.76 M | 8.88 M | 8.88 M | 8.88 M | 6.7 M | 7.21 M | 7.21 M | 7.21 M | 6.5 M | 6.87 M | 6.87 M | 6.87 M | 5.52 M | 7.48 M | 7.48 M | 7.48 M | 4.44 M | 4.75 M | 4.75 M | 4.75 M | 5.11 M | 5.33 M | 5.33 M | 5.33 M | 4.42 M | 5.07 M | 5.07 M | 5.07 M | 4.77 M | 4.38 M | 4.38 M | 4.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.4 M | 4.38 M | 7.95 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
128 M | $ 8.9 | 0.39 % | $ 593 M |  USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 26.03 | 0.75 % | $ 723 M | USA |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
1.22 B | $ 68.22 | 2.83 % | $ 26.6 B | USA |
 |
Guardant Health
GH
|
138 M | $ 87.75 | 0.66 % | $ 11 B | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 153.51 | 1.02 % | $ 7.61 B | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 17.49 | 0.98 % | $ 932 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | $ 103.9 | 0.04 % | $ 19.6 B | USA |
 |
IQVIA Holdings
IQV
|
3.4 B | $ 169.08 | 2.54 % | $ 29.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M |  China |
 |
Fulgent Genetics
FLGT
|
69 M | $ 15.52 | 3.81 % | $ 469 M | USA |
|
Biodesix
BDSX
|
8.6 M | $ 16.45 | -4.86 % | $ 2.13 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 100.08 | 2.53 % | $ 8.25 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
173 K | $ 2.86 | 0.83 % | $ 92.8 K | USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 194.79 | 1.77 % | $ 139 B | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.41 | 3.68 % | $ 423 M | USA |
 |
Illumina
ILMN
|
735 M | $ 122.27 | 2.51 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 198.48 | -0.23 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.17 B | $ 113.6 | 1.58 % | $ 34.5 B | USA |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.12 | 0.9 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 9.28 | 10.24 % | $ 263 M |  Israel |
 |
NeoGenomics
NEO
|
159 M | $ 8.32 | 0.97 % | $ 1.07 B | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.24 | 1.43 % | $ 2 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 78.64 | 0.18 % | $ 5.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
304 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
402 M | $ 454.41 | 0.17 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
778 M | $ 1 214.62 | 1.33 % | $ 25 B |  Schweiz |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 17.68 | 1.61 % | $ 396 M | USA |
 |
Twist Bioscience Corporation
TWST
|
57 M | $ 46.69 | 3.73 % | $ 2.79 B | USA |
 |
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
244 M | $ 199.75 | 1.05 % | $ 19.7 B | USA |